Navigation Links
BELLUS Health reports results for the fourth quarter of 2008
Date:2/26/2009

of the 2006 Notes discussed above. For additional information on the 2006 Notes, refer to the Annual report and Annual Information Form for the year ended December 31, 2008, that will be publicly filed in the near future, as well as other publicly filed documents.

In August 2006, the Company entered into a securities purchase agreement in respect of an equity line of credit facility (ELOC) with Cityplatz Limited (Cityplatz) that provided the Company up to $60,000,000 of funds in return for the issuance of common shares. As at December 31, 2008, the Company had not drawn any funds under the ELOC. Listing of the Company's securities on NASDAQ was a condition to drawdown under the terms of the ELOC concluded with Cityplatz. At the time of the Company's communication of its intention to delist, the estimated maximum annual amount potentially available was $1 million. As a result of the delisting of its common stock from NASDAQ in January 2009, the Company is no longer able to avail itself of funds under the ELOC.

As at December 31, 2008, the Company held $12,250,000 in principal value of third party ABCP, including $5,719,000 of third party ABCP acquired as part of the Innodia acquisition. These investments were due to mature in August 2007, but, as a result of a disruption in the credit markets, particularly in the ABCP market, they did not settle on maturity. On April 25, 2008, the restructuring plan announced by the Pan-Canadian Investors Committee (the Committee) in December 2007 was approved by the ABCP holders. Subsequent to year-end, on January 21, 2009, the Committee announced that the restructuring plan had been implemented. Pursuant to the terms of the restructuring plan, the Company received new floating rate interest-bearing notes (New notes) in exchange for its ABCP; $1,884,000 of MAV2 Class A-1 Notes, $2,265,000 of MAV2 Class A-2 Notes, $411,000 of MAV2 Class B Notes, $141,000 of MAV2 Class C Notes, $695,000 of MAV2 IA Tracking Notes, $5,0
'/>"/>

SOURCE BELLUS HEALTH INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine news :

1. At Annual and Special Meeting of Shareholders - Neurochem to officially adopt new name - BELLUS Health - And to provide update on programs including first new natural health product, VIVIMIND(TM)
2. BELLUS HEALTH reports results for first quarter of fiscal 2008
3. BELLUS Health to present at the Rodman and Renshaw 5th Annual Global Healthcare Conference
4. BELLUS Health announces closing of Innodia acquisition
5. BELLUS Health provides update on activities
6. BELLUS Health to present at the Rodman and Renshaw 10th Annual Healthcare Conference
7. BELLUS Health Reports Results for Third Quarter of Fiscal 2008 and on EMEA Update
8. BELLUS Health Announces Stock Listing Transfer from NASDAQ Global Market to NASDAQ Capital Market
9. BELLUS Health is Preparing to Voluntarily Delist from the NASDAQ Capital Market
10. BELLUS Health announces formal notice to voluntarily delist from NASDAQ
11. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on BELLUS Health Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... ASCNYC (ascnyc.org) is a New ... Yorkers living with HIV/AIDS and other chronic conditions ... and self-sufficiency. Each year, ASCNYC spotlights selected “Positive ... their tireless efforts. , Savills Studley ... been selected as this year’s honoree for sharing ...
(Date:10/20/2014)... October 20, 2014 T.E.N., a ... firm, announced today that William H. Murray, renowned ... 2014 ISE® Luminary Leadership Award winner. Presented annually, ... of an outstanding leader and industry practitioner for ... in advancing the information security industry. , Formerly ...
(Date:10/20/2014)... Zereana Jess-Huff, a 34-year-old mother, corporate executive and ... platform to think outside the bra. She doesn’t try to ... raise awareness about women’s other lady parts. , "We have ... the color pink and everybody knows what you’re talking about,” ... it has not been won when it comes to gynecologic ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 My Clients ... management software application. The new module enables easy ... receive full life-cycle quality care. , This application allows ... within their practice, attach a to-do item to a ... and even set up reoccurring reminders for follow-ups. ...
(Date:10/20/2014)... AttorneyOne.com, a recognized authority on law, update the website ... Sit and Slim II . , The FDA ... Sit and Slim II because it contains Sibutramine ... loss product on various websites and possibly in some retail ... safety reasons, can significantly increase blood pressure and/or pulse rate ...
Breaking Medicine News(10 mins):Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 2Health News:Savills Studley's Marc Shapses To Be Honored as 2014 "Positive Changemaker" by ASCNYC 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 2Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 3Health News:Bill Murray named 2014 ISE® Luminary Leadership Award Winner 4Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 2Health News:Ovarian Cancer Survivor Mrs. Maryland Urges Media to Think Outside the Bra 3Health News:My Clients Plus Announces New Workflow Management Software 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2
... variations that point to spectrum disorders , TUESDAY, March ... for brain proteins that seem to be linked to ... of the most comprehensive genetic analyses of association between ... spectrum disorder] risk," said Anthony Monaco, of the Wellcome ...
... ... Detox Protocol using Far Infrared. FIR therapy is a major key for returning us back ... ... Ph.D., RIET-1, a Doctor of Integrative Medicine and an Industrial Toxicologist, has dedicated a ...
... complications, costs, , TUESDAY, March 30 (HealthDay News) -- Current ... age 45, especially for those who are overweight, but new ... 30 and 45 for everyone . , When screening ... every year to five years, the average cost per quality-adjusted ...
... lung cancer per year in Germany are due to ... in the current edition of Deutsches rzteblatt International ... and his coauthors ( Dtsch Arztebl Int 2010; ... the results of relevant studies, the recently published S1 ...
... One in three South Asian, West Asian or Arab women ... say they have trouble accessing a doctor to address ... findings, from a new study by researchers at St. Michael,s ... finds this group and immigrant women and men are at ...
... ... Misunderstandings about proper use of antibiotics have the potential to ... report in the April issue of AJIC: American Journal of Infection ... Control and Epidemiology, Inc. (APIC). esearchers from Columbia University and MixedInk ...
Cached Medicine News:Health News:Scientist, Dr Staninger, Unlocks the Mystery of Morgellons Disease 2Health News:Scientist, Dr Staninger, Unlocks the Mystery of Morgellons Disease 3Health News:Diabetes Screening Should Start Sooner 2Health News:Diabetes Screening Should Start Sooner 3Health News:Minority women least likely to gain access to a doctor, study says 2Health News:Misinformation About Antibiotics Can Travel to Large Audience Via Twitter: Study 2Health News:Misinformation About Antibiotics Can Travel to Large Audience Via Twitter: Study 3Health News:Misinformation About Antibiotics Can Travel to Large Audience Via Twitter: Study 4Health News:Misinformation About Antibiotics Can Travel to Large Audience Via Twitter: Study 5
(Date:10/20/2014)... 2014 Valeritas, Inc., a leader in simple, ... Type 2 diabetes, announced today that it has received ... award was presented October 16 th at Cardinal,s ... . The Cardinal Health Supply ... of metrics specifically targeted at the importance of developing ...
(Date:10/20/2014)...  AnaptysBio, Inc., a leader in the discovery ... appointment of Marco Londei , M.D. as ... preclinical and clinical development of AnaptysBio,s proprietary antibody ... welcome Dr. Londei to AnaptysBio,s executive leadership team," ... Executive Officer of AnaptysBio. "Dr. Londei,s extensive expertise ...
(Date:10/20/2014)... Lpath, Inc. (NASDAQ: LPTN ... official notification from the European Patent Office that ... supporting its iSONEP™ and ASONEP™ programs. ... 2087002, claims compositions of matter related to sonepcizumab, ... iSONEP and ASONEP. Sonepcizumab is an antibody that ...
Breaking Medicine Technology:Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3AnaptysBio Appoints Dr. Marco Londei to Newly Created Chief Development Officer Position Clinical Immunologist to Lead AnaptysBio's Pipeline Advancement 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:KAPIDEX(TM) (dexlansoprazole) Renamed DEXILANT(TM) in U.S. to Avoid Name Confusion 2KAPIDEX(TM) (dexlansoprazole) Renamed DEXILANT(TM) in U.S. to Avoid Name Confusion 3KAPIDEX(TM) (dexlansoprazole) Renamed DEXILANT(TM) in U.S. to Avoid Name Confusion 4KAPIDEX(TM) (dexlansoprazole) Renamed DEXILANT(TM) in U.S. to Avoid Name Confusion 5KAPIDEX(TM) (dexlansoprazole) Renamed DEXILANT(TM) in U.S. to Avoid Name Confusion 6STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 2STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 3STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 4STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 5STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 6STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 7STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 8STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 9STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 10STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 11STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 12STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 13STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 14STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 15STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 16STELARA(TM) and REMICADE(R) Data in Treatment of Plaque Psoriasis to be Presented at American Academy of Dermatology (AAD) Meeting 17
... Multiplus no rub formula is the most ... All steps in one bottle without the ... your soft contact lenses and removes protein ... multi-purpose solution that contains Hydranate, a special ...
Grafton Trial Frame...
The award-winning new Universal Trial Frame (UB4), the ergonomic refraction design from Oculus that's easier to use, easier to wear....
Half Eye Trial Frame - Adult...
Medicine Products: